Australia's top brokers have been busy adjusting their estimates and recommendations again, leading to the release of a large number of broker notes this week.
Three broker buy ratings that have caught my eye are summarised below. Here's why brokers think these ASX 200 shares are in the buy zone:
Image source: Getty Images
ELMO Software Ltd (ASX: ELO)
According to a note out of Morgan Stanley, its analysts have retained their overweight rating and $9.00 price target on this HR and payroll software company's shares. This follows the release of its full year results on Thursday. Although the broker notes that ELMO's guidance for FY 2021 is a little softer than the market was expecting, it believes it is positive that it is actually in a position to provide guidance. Overall, it remains very positive on its long term prospects and retains its overweight rating. I agree with Morgan Stanley and feel the post-results pullback in the ELMO share price is a buying opportunity. Especially given its growth through acquisition plans.
Nick Scali Limited (ASX: NCK)
Analysts at Citi have retained their buy rating and lifted the price target on this furniture retailer's shares to $9.80. According to the note, the broker believes that Nick Scali's first half profit guidance of 50% to 60% growth may prove conservative. In addition to this, it believes the market is overlooking its strong balance sheet which could be used for acquisitions. I think Citi makes some great points and Nick Scali could be worth considering.
ResMed Inc. (ASX: RMD)
A note out of Morgans reveals that its analysts have retained their add rating and lifted the price target on this medical device company's shares to $29.33. The broker notes that ResMed's fourth quarter profit result was ahead of its expectations. This was driven by very strong ventilator sales due to the pandemic. And although it suspects that the first half of FY 2021 will be challenging, it appears optimistic that its outlook is very positive on the other side of the pandemic. Especially given its growing installed base and its large addressable market. I agree with Morgans and believe the recent weakness in the ResMed share price is a buying opportunity.
